Takeda Pharmaceutical Company Limited

Anand Panchal

Robert B Dubridge

Maia Vinogradova

Chad May

Patrick A Baeuerle

Holger Wesche

Luke Evnin

Jeanmarie Guenot

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Constrained conditionally activated binding proteins

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.

Single domain antigen binding domains that bind human Trop2

Growing community of inventors

San Francisco, CA, United States of America

Anand Panchal